Therapeutically targeting pro-tumorigenic epigenetic modifiers, such as G9a, may also serve as an effective method for treating genetically diverse MM subtypes and provide additional options for a currently incurable disease. The gene discussed is EHMT2; the disease is Miyoshi myopathy.